Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The plasma p‐tau217/BD‐tau ratio improves biomarker short‐term variability in memory clinic patients

1 Jul 2025

Abstract excerpt

Abstract INTRODUCTION Assessment of short‐term intra‐ and inter‐individual variability for Alzheimer's disease (AD) plasma biomarkers is essential for clinically relevant interpretation of biomarker levels. We hypothesized that the variability of plasma tau phosphorylated at threonine 217 (p‐tau217) could be reduced by combining it with a tau marker, plasma brain‐derived tau (BD‐tau), as the p‐tau217/BD‐tau...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Intracerebral and Subarachnoid Hemorrhage Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40827127
DOI: 10.1002/trc2.70143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The plasma p‐tau217/BD‐tau ratio improves biomarker short‐term variability in memory clinic patientsPMID 40827127Read ↗

CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progressionSemantic proximity Read ↗

Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity Read ↗

Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity Read ↗

Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction modelsSemantic proximity Read ↗

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity Read ↗

Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinicsSemantic proximity Read ↗

Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individualsSemantic proximity Read ↗

Biological variation estimates of Alzheimer’s disease plasma biomarkers in healthy individualsSemantic proximity Read ↗

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity Read ↗

Plasma biomarkers predict amyloid conversion and cognitive decline in cognitively unimpaired adultsSemantic proximity Read ↗

Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity Read ↗

Plasma p-tau217, p-tau181, and Aβ42 Predicts Amyloid PET Positivity in Cognitively Unimpaired AdultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.